Aplasia Cutis Congenita Associated with the Use of Antithyroid Medications during Pregnancy: A Case Report

Document Type : Case Report

Authors

1 Department of Delivery, Vice-Director of Da Nang Hospital for Women and Children, 402 Lê Văn Hiến, Khuê Mỹ, Ngũ Hành Sơn, Đà Nẵng, Vietnam

2 Department of Gynecology, Da Nang Hospital for Women and Children, 402 Lê Văn Hiến, Khuê Mỹ, Ngũ Hành Sơn, Đà Nẵng, Vietnam

3 Department of Dermatology, Đà Nẵng C Hospital, 122 Hải Phòng, Thạch Thang, Hải Châu, Đà Nẵng, Vietnam

Abstract

Background: Aplasia Cutis Congenita (ACC) is a rare malformation characterized by localized congenital absence of the skin which was first described by Cordon in 1767. ACC is estimated to occur in approximately 1 to 3 cases in 10000 live births. Many factors can contribute to developing ACC among which antithyroid medications were the strongest risk factor. A total of 61 cases of ACC were reported due to Methimazole/Carbimazole.
Case report: We report a female infant with ACC whose mother received Methimazole during pregnancy. Two small, punch-out lesions of the scalp were observed in diameters from 1.5 cm to 2 cm. The patient was treated with conservative care. Crusting and scab formation began on the fifth day. Minor, atrophied and hairless scars were found at the previous location of lesions by reexamining after 12 months.
Conclusion: The etiology of ACC has not yet been clearly defined. Methimazole may be a factor associated with this disorder. Management of ACC includes conservative care and surgery depending on the location and size of lesions, associated anomalies, and health of the infant.
 
 

Keywords

References

  1. Blionas A, Giakoumettis D, Antoniades E, Drosos E, Mitsios A, Plakas S, Sfakianos G, Themistocleous MS. Aplasia cutis congenita: Two case reports and discussion of the literature. Surg Neurol Int. 20179;8:273.
  2. Mukhtar-Yola M, Mshelia L, Mairami AB, et al. Aplasia cutis congenita: a report of two cases from National Hospital Abuja, Nigeria and review of the literature. Pan Afr Med J. 2020;36:291.
  3. Dahmardehei M. A rare case of aplasia cutis congenita. Acta Med Iran. 201330;51(5):341-4
  4. Cohen MI, Ribeiro JT, Costa CA, Westphal FL. Aplasia Cutis Congenita. Case report and literature review. J Bras Neurocicur. 2019;30(3):105-111.
  5. Milham Jr S, Elledge W. Maternal methimazole and congenitaldefects in children. Teratology. 1972;5:
    125–126.
  6. Milham Jr S. Scalp defects in infants of mothers treated for hyperthyroidism with methimazole
    or carbimazole during pregnancy. Teratology. 1985;32:321.
  7. Sachs C, Tebacher-Alt M, Mark M, Cribier B, Lipsker D. Aplasie cutanée congénitale et antithyroïdiens de synthèse au cours de la grossesse : série de cas et revue de la littérature [Aplasia cutis congenita and antithyroid medications during pregnancy: Case series and literature review]. Ann Dermatol Venereol. 2016;143(6-7):423-35.
  8. Yang MY, Ha DL, Kim HS, Ko HC, Kim BS, Kim MB. Aplasia cutis congenita in Korea: Single center experience and literature review. Pediatr Int. 2020;62(7):804-809.
  9. Lei GF, Zhang JP, Wang XB, et al. Treating aplasia cutis congenita in a newborn with the combination of ionic silver dressing and moist exposed burn ointment: A case report. World J Clin Cases. 2019;7(17):2611-2616.
  10. Eghbalian Aplasia Cutis Congenita after Methimazole Exposure in Utero; A case Report and Literature Review. Iran J Pediatr. 2007;17(3): 293-296.
  11. Frieden IJ. Aplasia cutis congenita: A clinical review and proposal for classification. J Am Acad Dermatol. 1986;14(4):646-60.
  12. Humphrey SR, Hu X, Adamson K, Schaus A, Jensen JN, Drolet B. A practical approach to the evaluation and treatment of an infant with aplasia cutis congenita. J Perinatol. 2018;38(2):110-117.
  13. Kojmane W, Atmani S. Aplasia cutis congenita suite à une exposition in utero au carbimazole [A case of aplasia cutis congenita following in utero exposure to carbimazole]. Ann Dermatol Venereol. 2020;
    147(1):76-77.
  14. Andersen SL, Andersen S. Antithyroid drugs and birth defects. Thyroid Res. 2020; 13:11.
  15. Song R, Lin H, Chen Y, Zhang X, Feng W. Effects of methimazole and propylthiouracil exposure during pregnancy on the risk of neonatal congenital malformations: A meta-analysis. PLoS One. 2017;12(7):e0180108.
  16. Morales DR, Fonkwen L, Nordeng HME. Antithyroid drug use during pregnancy and the risk of birth defects in offspring: systematic review and
    meta-analysis of observational studies with methodological considerations. Br J Clin Pharmacol. 2021;87(10):3890-3900
  17. Arslanca SB, Arslanca T, Koç A. Aplasia cutis congenita: a case report. J Obstet Gynaecol. 2019;39(6):860-861.
  18. Perry BM, Maughan CB, Crosby MS, Hadenfeld SD. Aplasia cutis congenita type V: a case report and review of the literature. Int J Dermatol. 2017;56(6):e118-e121.
  19. GassenmaierM, BösmüllerH, Metzler Aplasia cutis congenita of the scalp: Histopathologic features and clinicopathologic correlation in a case series. J Cutan Pathol. 2020;47:439–445.
  20. Barcot Z, Baskovic M, Car A, Juric M. Aplasia cutis congenita of the scalp: The success of conservative approach in treatment of a large defect. Indian J Paediatr Dermatol. 2019;20:166-8.
  21. Lee YJ, Kim SA, Moon SH. An Aplasia Cutis Congenita: Suggestion of Management Algorithm. J Craniofac Surg. 2019;30(8):2493-2496.
Iranian Journal of Neonatology
Volume 13, Issue 2
April 2022
Pages 125-129

Files

Share

How to cite

Statistics